X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4657) 4657
humans (4221) 4221
braf (3356) 3356
mutation (2672) 2672
oncology (2463) 2463
proto-oncogene proteins b-raf - genetics (2293) 2293
cancer (2271) 2271
melanoma (2139) 2139
female (2026) 2026
male (1938) 1938
middle aged (1650) 1650
braf mutation (1389) 1389
adult (1370) 1370
aged (1332) 1332
tumors (1164) 1164
pathology (1135) 1135
genetic aspects (1108) 1108
gene mutations (975) 975
metastasis (906) 906
prognosis (898) 898
vemurafenib (860) 860
carcinoma (809) 809
melanoma - genetics (792) 792
metastatic melanoma (784) 784
analysis (764) 764
colorectal cancer (763) 763
research (757) 757
thyroid neoplasms - genetics (747) 747
cell biology (737) 737
mutations (723) 723
thyroid cancer (714) 714
braf mutations (702) 702
care and treatment (700) 700
animals (678) 678
braf v600e mutation (678) 678
immunohistochemistry (675) 675
neoplasms (673) 673
aged, 80 and over (656) 656
melanoma - drug therapy (648) 648
melanoma - pathology (648) 648
cell line, tumor (646) 646
thyroid neoplasms - pathology (645) 645
survival (635) 635
expression (634) 634
proto-oncogene proteins b-raf - metabolism (584) 584
kinases (567) 567
article (557) 557
diagnosis (552) 552
proto-oncogene proteins b-raf - antagonists & inhibitors (537) 537
colorectal neoplasms - genetics (523) 523
kras (522) 522
medicine & public health (520) 520
dna mutational analysis (515) 515
microsatellite instability (515) 515
endocrinology & metabolism (502) 502
health aspects (489) 489
dermatology (478) 478
young adult (475) 475
activation (464) 464
b-raf (459) 459
surgery (455) 455
chemotherapy (453) 453
antineoplastic agents - therapeutic use (441) 441
biomarkers, tumor - genetics (432) 432
adolescent (408) 408
digestive system diseases (405) 405
resistance (405) 405
gene (397) 397
pathway (397) 397
development and progression (395) 395
papillary thyroid carcinoma (395) 395
open-label (393) 393
biochemistry & molecular biology (389) 389
skin neoplasms - pathology (388) 388
patients (387) 387
mutation - genetics (383) 383
proteins (383) 383
mice (382) 382
skin neoplasms - genetics (378) 378
therapy (375) 375
retrospective studies (374) 374
signal transduction (370) 370
thyroid cancer, papillary (365) 365
colorectal neoplasms - pathology (360) 360
gene expression (358) 358
malignant-melanoma (355) 355
protein kinase inhibitors - pharmacology (354) 354
acquired-resistance (353) 353
braf v600e (351) 351
dabrafenib (350) 350
abridged index medicus (347) 347
endocrine system diseases (344) 344
genes (336) 336
targeted therapy (334) 334
ras proteins - genetics (333) 333
immunotherapy (327) 327
metastases (327) 327
treatment outcome (326) 326
inhibition (325) 325
colon-cancer (323) 323
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6553) 6553
French (51) 51
German (38) 38
Spanish (19) 19
Korean (12) 12
Russian (8) 8
Polish (7) 7
Chinese (5) 5
Japanese (4) 4
Portuguese (3) 3
Czech (1) 1
Hungarian (1) 1
Persian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 09/2014, Volume 38, Issue 9, pp. 1235 - 1241
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 508, Issue 1, pp. 118 - 122
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably(1,2).... 
GROWTH-FACTOR RECEPTOR | BRAF INHIBITOR | RAF INHIBITION | CELLS | MULTIDISCIPLINARY SCIENCES | IMPROVED SURVIVAL | DIFFERENTIATION | C-JUN | CANCER | EXPRESSION | EGFR | Receptor, Epidermal Growth Factor - genetics | Humans | Receptor Protein-Tyrosine Kinases - biosynthesis | Cellular Senescence - drug effects | Melanoma - enzymology | Antineoplastic Agents - administration & dosage | Receptor, Platelet-Derived Growth Factor beta - genetics | Indoles - administration & dosage | Mitogen-Activated Protein Kinase Kinases - metabolism | Receptor, Epidermal Growth Factor - metabolism | Flow Cytometry | Melanoma - genetics | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | SOXE Transcription Factors - deficiency | Proto-Oncogene Proteins B-raf - metabolism | Receptor, Platelet-Derived Growth Factor beta - metabolism | Receptor, Epidermal Growth Factor - biosynthesis | Gene Library | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Transforming Growth Factor beta - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Transforming Growth Factor beta - metabolism | Receptor, Platelet-Derived Growth Factor beta - biosynthesis | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | SOXE Transcription Factors - genetics | Proteins | Biopsy | Rodents | Genes | Melanoma | Mutation | Kinases | Drug resistance | Patients | Tumors | Index Medicus
Journal Article
The Journal of Pathology, ISSN 0022-3417, 04/2014, Volume 232, Issue 5, pp. 492 - 498
Ameloblastoma is a benign but locally infiltrative odontogenic neoplasm. Although ameloblastomas rarely metastasise, recurrences together with radical surgery... 
targeted therapy | odontogenic tumour | BRAF | oncogenic mutation | EGFR | ameloblastoma | GEFITINIB | TRANSGENIC MOUSE | PATHOLOGY | METASTATIC COLORECTAL-CANCER | PANITUMUMAB | LUNG-CANCER | ONCOLOGY | FACTOR RECEPTOR EXPRESSION | KRAS | EGF RECEPTOR | CELL-LINE | ERLOTINIB | Ameloblastoma - drug therapy | Receptor, Epidermal Growth Factor - genetics | Jaw Neoplasms - drug therapy | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Ameloblastoma - enzymology | Molecular Targeted Therapy | Jaw Neoplasms - pathology | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Receptor, Epidermal Growth Factor - metabolism | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Ameloblastoma - pathology | Antineoplastic Agents - pharmacology | Jaw Neoplasms - enzymology | Proto-Oncogene Proteins B-raf - metabolism | Cell Survival - drug effects | Genetic Predisposition to Disease | Gene Frequency | Ameloblastoma - genetics | Phenotype | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Adolescent | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Protein Kinase Inhibitors - pharmacology | Mutation | Receptor, ErbB-4 | Jaw Neoplasms - genetics | Immunohistochemistry | Genetic aspects | Gene mutations | Analysis | Pathogenesis | Index Medicus | Original Papers
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 12/2011, Volume 17, Issue 24, pp. 7595 - 7604
Purpose: Malignant astrocytomas (MA) are aggressive central nervous system tumors with poor prognosis. Activating mutation of BRAF (BRAF(V600E)) has been... 
ONCOGENIC RAS | ONCOLOGY | DIAGNOSED GLIOBLASTOMA-MULTIFORME | WILD-TYPE BRAF | TYROSINE KINASES | B-RAF | MELANOMA-CELLS | HIGH-GRADE GLIOMAS | PHARMACOLOGICAL INHIBITION | EGFR AMPLIFICATION | RADIATION-THERAPY
Journal Article
PLOS ONE, ISSN 1932-6203, 01/2012, Volume 7, Issue 1, pp. e29336 - e29336
Journal Article
JAMA, ISSN 0098-7484, 04/2013, Volume 309, Issue 14, pp. 1493 - 1501
Journal Article
Lancet Oncology, ISSN 1470-2045, 07/2016, Volume 17, Issue 7, pp. 984 - 993
Journal Article
Journal Article
Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon... 
PANITUMUMAB | TARGET | CETUXIMAB | MELANOMA | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PAPILLARY THYROID-CARCINOMA | KRAS | METASTATIC COLORECTAL-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors | Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 03/2013, Volume 108, Issue 4, pp. 924 - 931
Journal Article